Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
MCT team meets Tunisian health Minister
News / July 15, 2019
MCT at PCMG 2020 Live
News / June 24, 2020